|
126 Companies |
|
141 Products |
|
141 Products |
|
89 Mechanisms of Action |
|
9 Trials |
|
1237 News |
|
| 12345678910111213...2425» |
- | NN1213 / Novo Nordisk
Phase classification, Enrollment change, Metastases: Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - May 31, 2023
P1, N=50, Completed, Sponsor: University of Chicago
Phase classification: P1/2 --> P1 | N=19 --> 50
- | Trial completion, Metastases: Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach (clinicaltrials.gov) - Apr 20, 2019
P2, N=61, Completed, Sponsor: Case Comprehensive Cancer Center
Phase classification: P1/2 --> P1 | N=19 --> 50 Active, not recruiting --> Completed
- | carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Metastases: Gastric Cancer RAD001 Study (clinicaltrials.gov) - Apr 20, 2019
P1/2, N=35, Completed, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2019 --> Mar 2019
- | Enrollment change, Trial withdrawal, Surgery: Prospective Cohort Study for Analyzing the Effect of Gastric Cancer Surgery to the Metabolic Syndrome and Insulin Resistance (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=0, Withdrawn, Sponsor: Yonsei University
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2019 --> Mar 2019 N=270 --> 0 | Recruiting --> Withdrawn
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=96, Completed, Sponsor: Yonsei University
N=270 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | Trial completion date: May 2016 --> Jun 2018 | Trial primary completion date: Dec 2015 --> Jun 2018
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change: Usefulness of Probe-based Confocal Laser Endo-microscopy in Delineation of Margin of Early Gastric Cancer for Endoscopic Submucosal Dissection (clinicaltrials.gov) - Apr 19, 2019
P=N/A, N=101, Completed, Sponsor: Yonsei University
Recruiting --> Completed | Trial completion date: May 2016 --> Jun 2018 | Trial primary completion date: Dec 2015 --> Jun 2018 Recruiting --> Completed | N=62 --> 101
- | NN1213 / Novo Nordisk, Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion, Combination therapy: The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer (clinicaltrials.gov) - Apr 19, 2019
P=N/A, N=153, Completed, Sponsor: Yonsei University
Recruiting --> Completed | N=62 --> 101 Recruiting --> Completed
- | NN1213 / Novo Nordisk
Biomarker, Trial completion date, Trial primary completion date: Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea (clinicaltrials.gov) - Mar 18, 2019
P=N/A, N=108, Recruiting, Sponsor: Yonsei University
Recruiting --> Completed Trial completion date: Nov 2018 --> Dec 2023 | Trial primary completion date: Oct 2018 --> Dec 2023
- | Enrollment change, Trial withdrawal, BRCA Biomarker: Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer (clinicaltrials.gov) - Mar 9, 2019
P=N/A, N=0, Withdrawn, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Nov 2018 --> Dec 2023 | Trial primary completion date: Oct 2018 --> Dec 2023 N=1905 --> 0 | Recruiting --> Withdrawn
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Cytoprotective Agent and Peptic Ulcer in Dual Antiplatelet :RCT (clinicaltrials.gov) - Feb 27, 2019
P2/3, N=142, Completed, Sponsor: King Chulalongkorn Memorial Hospital
N=1905 --> 0 | Recruiting --> Withdrawn Suspended --> Completed | Trial completion date: Dec 2015 --> Jun 2018 | Trial primary completion date: Jun 2015 --> Jun 2017
- | carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Gastric Cancer RAD001 Study (clinicaltrials.gov) - Feb 22, 2019
P1/2, N=35, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Suspended --> Completed | Trial completion date: Dec 2015 --> Jun 2018 | Trial primary completion date: Jun 2015 --> Jun 2017 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Trial completion date, Trial primary completion date, Metastases: PaFLO: FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer (clinicaltrials.gov) - Feb 12, 2019
P2, N=75, Completed, Sponsor: Charite University, Berlin, Germany
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: May 2015 --> Dec 2017 | Trial primary completion date: May 2014 --> Dec 2017
- | oxaliplatin / Generic mfg., capecitabine / Generic mfg., celecoxib oral / Generic mfg.
Enrollment change, Trial termination, Metastases: Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma (clinicaltrials.gov) - Feb 8, 2019
P2, N=4, Terminated, Sponsor: University of California, Irvine
Trial completion date: May 2015 --> Dec 2017 | Trial primary completion date: May 2014 --> Dec 2017 N=20 --> 4 | Completed --> Terminated; Closed due to poor accrual
- | Trial completion, Trial completion date: Urgent vs. Early Endoscopy in High Risk Patients With Upper Gastrointestinal Bleeding (UGIB) (clinicaltrials.gov) - Feb 1, 2019
P=N/A, N=516, Completed, Sponsor: Chinese University of Hong Kong
N=20 --> 4 | Completed --> Terminated; Closed due to poor accrual Recruiting --> Completed | Trial completion date: Jun 2019 --> Nov 2018
- | NN1213 / Novo Nordisk
Trial completion, Biopsy: Flexible Endoscopy Biopsies for Submucous Tumors With a New Drill Instrument (clinicaltrials.gov) - Feb 1, 2019
P=N/A, N=10, Completed, Sponsor: Region Skane
Recruiting --> Completed | Trial completion date: Jun 2019 --> Nov 2018 Recruiting --> Completed
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Metastases: Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer (clinicaltrials.gov) - Jan 29, 2019
P2, N=180, Completed, Sponsor: Yonsei University
Recruiting --> Completed Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Biomarker, Trial completion, Enrollment change, Trial completion date, Metastases: Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. (clinicaltrials.gov) - Jan 25, 2019
P2, N=21, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed Recruiting --> Completed | N=127 --> 21 | Trial completion date: Nov 2019 --> Apr 2017
- ||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Trial completion date, Trial primary completion date, Metastases: S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients (clinicaltrials.gov) - Jan 23, 2019
P3, N=576, Completed, Sponsor: Sun Yat-sen University
Recruiting --> Completed | N=127 --> 21 | Trial completion date: Nov 2019 --> Apr 2017 Recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Dec 2018
- ||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial termination, Metastases: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor (clinicaltrials.gov) - Jan 22, 2019
P2, N=53, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Dec 2018 Completed --> Terminated; The applicant decided to close the study
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: An Effect of an Individualized Physical Activity Intervention for Gastric Cancer Patient Undergoing Minimally Invasive Gastrectomy: a Phase III, Prospective Randomized Controlled Trial (clinicaltrials.gov) - Jan 22, 2019
P3, N=70, Completed, Sponsor: Yonsei University
Completed --> Terminated; The applicant decided to close the study Recruiting --> Completed | Trial completion date: Nov 2017 --> Jul 2017 | Trial primary completion date: Nov 2017 --> Jul 2017
- | NN1213 / Novo Nordisk
Enrollment change, Trial withdrawal: A Study on Precutting Methods of Endoscopic Submucosal Dissection for Gastric Neoplasms Located at Lesser Curvature Side of Antrum (clinicaltrials.gov) - Jan 16, 2019
P=N/A, N=0, Withdrawn, Sponsor: Yonsei University
Recruiting --> Completed | Trial completion date: Nov 2017 --> Jul 2017 | Trial primary completion date: Nov 2017 --> Jul 2017 N=86 --> 0 | Recruiting --> Withdrawn
- veliparib (ABT-888) / AbbVie
Trial termination, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 3, 2019
P1, N=16, Terminated, Sponsor: National Cancer Institute (NCI)
N=86 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Terminated
- || azacitidine / Generic mfg.
Trial completion: VEOX: Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer (clinicaltrials.gov) - Dec 12, 2018
P1, N=12, Completed, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- | Trial completion, Phase classification, Metastases: Efficacy of Laparoscopic Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (clinicaltrials.gov) - Nov 29, 2018
P=N/A, N=1050, Completed, Sponsor: Ajou University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P3 --> PN/A
- | Trial completion: Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis (clinicaltrials.gov) - Nov 6, 2018
P2, N=50, Completed, Sponsor: G
Active, not recruiting --> Completed | Phase classification: P3 --> PN/A Recruiting --> Completed
- || Avastin (bevacizumab) / Roche
Trial completion, Metastases: Avastin and Taxotere for Esophagogastric Cancer (clinicaltrials.gov) - Nov 1, 2018
P2, N=42, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor (clinicaltrials.gov) - Oct 26, 2018
P1/2, N=59, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer (clinicaltrials.gov) - Oct 10, 2018
P3, N=120, Completed, Sponsor: Wakayama Medical University
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion, Phase classification: 124I-FIAU Imaging in EBV and KSHV Associated Cancers (clinicaltrials.gov) - Sep 17, 2018
P=N/A, N=12, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting --> Completed Recruiting --> Completed | Phase classification: P1 --> PN/A
- | SM04755 / Biosplice Therap
Trial completion, Enrollment change, Metastases: Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer (clinicaltrials.gov) - Sep 7, 2018
P1, N=13, Completed, Sponsor: Samumed LLC
Recruiting --> Completed | Phase classification: P1 --> PN/A Suspended --> Completed | N=25 --> 13
- | NN1213 / Novo Nordisk
Trial primary completion date, Metastases: Neo-CRAG: Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer (clinicaltrials.gov) - Aug 31, 2018
P3, N=620, Recruiting, Sponsor: Sun Yat-sen University
Suspended --> Completed | N=25 --> 13 Trial primary completion date: Jun 2022 --> Dec 2023
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment change, Trial completion date, Trial termination, Combination therapy, Metastases: FluoHeart: Effects of S-1 and Capecitabine on Coronary Artery Blood Flow (clinicaltrials.gov) - Aug 28, 2018
P2, N=20, Terminated, Sponsor: Heikki Joensuu
Trial primary completion date: Jun 2022 --> Dec 2023 N=40 --> 20 | Trial completion date: Aug 2019 --> Aug 2018 | Recruiting --> Terminated; Slow accrual
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date: VOLGACORE: Volatile Markers in Digestive Cancer (clinicaltrials.gov) - Aug 21, 2018
P=N/A, N=2022, Completed, Sponsor: University of Latvia
N=40 --> 20 | Trial completion date: Aug 2019 --> Aug 2018 | Recruiting --> Terminated; Slow accrual Recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2017
- | Trial completion, Enrollment change: Frequency of Formula Change Prior to the Accurate Diagnosis of Pyloric Stenosis (clinicaltrials.gov) - Aug 17, 2018
P=N/A, N=20, Completed, Sponsor: Maimonides Medical Center
Recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2017 Recruiting --> Completed | N=100 --> 20
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Grant: Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer (clinicaltrials.gov) - Aug 16, 2018
P2, N=60, Completed, Sponsor: Montefiore Medical Center
Recruiting --> Completed | N=100 --> 20 Active, not recruiting --> Completed
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion date, Trial primary completion date, Metastases: S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients (clinicaltrials.gov) - Jul 24, 2018
P3, N=544, Recruiting, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed Trial completion date: Mar 2018 --> Sep 2018 | Trial primary completion date: Mar 2018 --> Aug 2018
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Metastases: Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Jul 19, 2018
P1/2, N=63, Completed, Sponsor: Capital Medical University
Trial completion date: Mar 2018 --> Sep 2018 | Trial primary completion date: Mar 2018 --> Aug 2018 Active, not recruiting --> Completed
- | Trial completion date: Urgent vs. Early Endoscopy in High Risk Patients With Upper Gastrointestinal Bleeding (UGIB) (clinicaltrials.gov) - Jul 18, 2018
P=N/A, N=516, Recruiting, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed Trial completion date: Nov 2018 --> Jun 2019
- | oxaliplatin / Generic mfg., capecitabine / Generic mfg.
Enrollment change, Trial termination, Metastases: Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer (clinicaltrials.gov) - Jul 16, 2018
P2, N=10, Terminated, Sponsor: Medical University of South Carolina
Trial completion date: Nov 2018 --> Jun 2019 N=46 --> 10 | Completed --> Terminated; due to low accrual
- | NN1213 / Novo Nordisk
Biomarker, Trial completion, Trial primary completion date: VARIANZ: Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer (clinicaltrials.gov) - Jul 11, 2018
P=N/A, N=549, Completed, Sponsor: University of Leipzig
N=46 --> 10 | Completed --> Terminated; due to low accrual Recruiting --> Completed | Trial primary completion date: Feb 2017 --> Jan 2018
- |||| NN1213 / Novo Nordisk
Trial completion date, Trial termination, Trial primary completion date: MMS-TM: Validation of MMS Test for Cancer Monitoring (clinicaltrials.gov) - Jun 21, 2018
P=N/A, N=100, Terminated, Sponsor: MedInnovation GmbH
Recruiting --> Completed | Trial primary completion date: Feb 2017 --> Jan 2018 Trial completion date: Dec 2018 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jun 2018; insufficient recruitment on the part of clinic; study will not resume
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Enrollment change, Trial completion date: Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis (clinicaltrials.gov) - May 4, 2018
P1, N=12, Completed, Sponsor: The University of Hong Kong
Trial completion date: Dec 2018 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jun 2018; insufficient recruitment on the part of clinic; study will not resume Recruiting --> Completed | N=18 --> 12 | Trial completion date: Sep 2018 --> Mar 2018
- ||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial completion, Metastases: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor (clinicaltrials.gov) - Apr 26, 2018
P2, N=53, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed | N=18 --> 12 | Trial completion date: Sep 2018 --> Mar 2018 Terminated --> Completed
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial termination, Metastases: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor (clinicaltrials.gov) - Apr 18, 2018
P2, N=53, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Terminated --> Completed Recruiting --> Terminated; The applicant decided to close the study
- | cabazitaxel / Generic mfg.
Trial completion, Metastases: Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Apr 18, 2018
P2, N=65, Completed, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Recruiting --> Terminated; The applicant decided to close the study Active, not recruiting --> Completed
- | Trial completion, Enrollment change: Screening for Gastric Cancer in High-risk Population (clinicaltrials.gov) - Apr 11, 2018
P=N/A, N=80, Completed, Sponsor: Rabin Medical Center
Active, not recruiting --> Completed Recruiting --> Completed | N=200 --> 80
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy, Metastases: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer (clinicaltrials.gov) - Apr 6, 2018
P2a, N=30, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=200 --> 80 Active, not recruiting --> Completed
- | Trial completion, Metastases: Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction (clinicaltrials.gov) - Mar 30, 2018
P2, N=73, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Herceptin (trastuzumab) / Roche
Phase classification: EVIDENCE: A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer (clinicaltrials.gov) - Mar 30, 2018
P, N=1600, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Phase classification: P=N/A --> P
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Trial termination, Combination therapy, Monotherapy, Metastases: Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer (clinicaltrials.gov) - Mar 26, 2018
P3, N=400, Terminated, Sponsor: Kuhnil Pharmaceutical Co., Ltd.
Phase classification: P=N/A --> P Active, not recruiting --> Terminated